MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test ...
Cambridge, MA, April 26, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the American Medical Association (AMA) has issued a new CPT® Proprietary Laboratory Analyses (PLA) code ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have signed an agreement to ...
MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...
ExoDx Prostate (IntelliScore) is a clinically validated, non-digital rectal exam (DRE) urine-based liquid biopsy test that predicts the presence of high-grade (Gleason score ≥7) prostate cancer for ...
(MENAFN- PR Newswire) Medicare contractor National government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly ...
ExoDx Lung(ALK) is the World’s First Non-invasive Test Allowing Identification of Specific ALK Fusions Using Exosomal RNA-Based Liquid Biopsy ExoDx Lung(ALK) is the First in a Series of Exosomal ...
ExoDx integration and 2026 targets: Select mdx customer transitions are complete and sales integration should finish by end‑Q1, management expects ExoDx to contribute >$20M in 2026 and aims for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results